Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

Robert Tuttle, M.D.

Committees: Endocrinologic & Metabolic Drugs Advisory Committee and the Advisory Committee for Pharmaceutical Science Meeting

Meeting Date: October 4, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the joint committees' discussions of FDA's efforts to assess the product quality of currently marketed levothroxine sodium drug products. Earlier this year, FDA requested that manufacturers of currently marketed levothroxine sodium products provide to it certain product release and stability information. The joint committee will consider FDA's analyses and any clinical significance. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	**Nature**	**Magnitude**
Related Consulting	Affected Firm	Less than $10,001 per year.
Related Speaking	Affected Firm	Less than $10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/S/ 9/14/06

Signature of SGE Date